Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update
09 mai 2018 16h20 HE
|
Otonomy, Inc.
SAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial...
Otonomy to Report First Quarter 2018 Financial Results and Provide Corporate Update
02 mai 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
08 mars 2018 16h24 HE
|
Otonomy, Inc.
Type C meeting completed with FDA for OTIVIDEX™ in Ménière’s disease Consistent with prior guidance, pivotal trial for OTIVIDEX to start mid-2018 Conference call and webcast today at 4:30 p.m. EST ...
Otonomy to Present at Cowen and Company Health Care Conference
06 mars 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Otonomy Announces FDA Approval of OTIPRIO(R) for Acute Otitis Externa
02 mars 2018 11h55 HE
|
Otonomy, Inc.
SAN DIEGO, March 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that the...
Otonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update
01 mars 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy Announces Plan to Focus Resources on Development Programs
27 nov. 2017 16h30 HE
|
Otonomy, Inc.
Company to focus resources on completing OTIVIDEX™ clinical development to support U.S. regulatory approval for Ménière’s disease, and advancing multiple other programs addressing hearing loss and...
Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update
08 nov. 2017 16h12 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease
08 nov. 2017 16h05 HE
|
Otonomy, Inc.
Achieved primary endpoint (p value = 0.029)Company plans to meet with FDA to discuss results and clinical requirements for registrationManagement will review results during third quarter conference...
Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update
01 nov. 2017 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...